SHASQI
19 Apr 2022
Trial Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Acronym:
SHASQI
ACTRN/NCT /ethics:
NCT04106492
Scientific title:
A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients with Advanced Solid Tumors
Sponsor / Cooperative group:
Shasqi, Inc.
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2020-08-01 |
| Anticipated End Date | 2026-07-09 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Vineet Kwatra |
| Recruitment Status | Recruiting |